(Q30607148)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529375%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

5 November 2020

Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529375%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

5 November 2020

1 reference

5 November 2020

health care outcome assessment

1 reference

PubMed

4 November 2020

angiogenesis inhibitor

1 reference

5 November 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529375%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

6

Timothy F Cloughesy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529375%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

3

Lauren E Abrey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529375%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

David R Macdonald

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529375%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Gudrun Zahlmann

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529375%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Yannick Kerloëguen

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529375%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

1 May 2013

8 references

14 March 2019

3 April 2019

25 April 2019

20 June 2019

22 June 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529375%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

4 November 2020

5 November 2020

Current Neurology and Neuroscience Reports

8 references

14 March 2019

3 April 2019

25 April 2019

20 June 2019

22 June 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529375%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

4 November 2020

5 November 2020

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529375%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529375%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

347

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529375%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial 2.0 Generic

27 February 2020

copyright license

start time

26 March 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s11910-013-0347-2

0 references

cites work

Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

High levels of cellular proliferation predict pseudoprogression in glioblastoma patients

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Clinical trial end points for high-grade glioma: the evolving landscape.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Response assessment in neuro-oncology

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Pseudoprogression and pseudoresponse in the treatment of gliomas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Response criteria for glioma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Malignant gliomas in adults

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Brain tumor imaging in clinical trials

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Angiogenesis in brain tumours

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Reporting results of cancer treatment

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

The Mini-Mental State Examination: A Comprehensive Review

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Radiographic patterns of relapse in glioblastoma.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Steroid-induced CT changes in patients with recurrent malignant glioma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

Assessment of intra-observer variability in measurement of high-grade brain tumors

28 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0347-2

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0347-2

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0347-2

Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0347-2

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0347-2

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0347-2

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0347-2

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0347-2

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0347-2

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0347-2

The CareGiver Oncology Quality of Life questionnaire (CarGOQoL): development and validation of an instrument to measure the quality of life of the caregivers of patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0347-2

Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3631110

10.1007/S11910-013-0347-2

25 November 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529375%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

27 February 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529375%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23529375%20AND%20SRC:MED&resulttype=core&format=json